ライフサイエンスコーパス: chronic hepatitis C

1 and fibrosis in two cohorts of patients with chronic hepatitis C.

2 USION: FD is more prevalent in patients with chronic hepatitis C.

3 as highlighted by the case of the therapy of chronic hepatitis C.

4 and averted 252 (134-389) deaths related to chronic hepatitis C.

5 nse to peginterferon alpha/ribavirin (PR) in chronic hepatitis C.

6 hly effective for treatment of patients with chronic hepatitis C.

7 f patients with alcohol-related cirrhosis or chronic hepatitis C.

8 n the response to IFN-alpha-based therapy of chronic hepatitis C.

9 g pegIFN-alpha injection in 18 patients with chronic hepatitis C.

10 FN)-induced viral clearance in patients with chronic hepatitis C.

11 antiviral responses in patients affected by chronic hepatitis C.

12 on sustained viral response in patients with chronic hepatitis C.

13 s patient-reported outcomes in patients with chronic hepatitis C.

14 ts for prevention of hepatocarcinogenesis in chronic hepatitis C.

15 nt scale-up, which has reduced the burden of chronic hepatitis C.

16 ng the use of direct-acting agents (DAAs) in chronic hepatitis C [2].

17 ated with reduced hepcidin expression, e.g., chronic hepatitis C, alcoholic liver disease, or heredit

18 This study included 252 patients with chronic hepatitis C and 150 healthy volunteers.

19 onsistent with these findings, patients with chronic hepatitis C and nonalcoholic steatohepatitis sig

20 can capture nonlinear disease progression in chronic hepatitis C and thus outperform baseline models.

21 ng cholangitis, alcoholic liver disease, and chronic hepatitis C), and human cholangiocytes expressed

22 three PIs have been approved for therapy of chronic hepatitis C, and several others are in developme

23 udy, we elucidate the potential link between chronic hepatitis C-associated inflammation and alterati

24 % credible interval 30-44), the incidence of chronic hepatitis C by 37% (29-44), and chronic hepatiti

25 atments have reduced the prevalence of adult chronic hepatitis C by a median 37% (95% credible interv

26 Chronic hepatitis C can result in progressive liver dise

27 Here, we demonstrate in 1689 patients with chronic hepatitis C (CHC) (1,501 with CHC and 188 with H

28 ] allele is more represented in HCC cases in chronic hepatitis C (CHC) and alcoholic liver disease (A

29 Most of these markers have been developed in chronic hepatitis C (CHC) and nonalcoholic fatty liver d

30 d genes (ISGs) in the liver of patients with chronic hepatitis C (CHC) are not known.

31 FLD and liver damage progression in NASH and chronic hepatitis C (CHC) by still undefined mechanisms,

32 Patients with chronic hepatitis C (CHC) exhibit reduced work productiv

33 mproving prediction of treatment outcomes in chronic hepatitis C (CHC) genotype 4 (G4) is necessary t

34 Approximately 50% of patients with chronic hepatitis C (CHC) have a sustained virologic res

35 Approximately 50% of patients with chronic hepatitis C (CHC) have ongoing expression of int

36 In resource-rich countries, chronic hepatitis C (CHC) infection is associated with a

37 Liver mortality among individuals with chronic hepatitis C (CHC) infection is common, but the r

38 the standard of care (SOC) for patients with chronic hepatitis C (CHC) infection.

39 rowing evidence that vitamin D is related to chronic hepatitis C (CHC) pathogenicity.

40 proving hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication wit

41 (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated accordi

42 compensation, and their time relationship in chronic hepatitis C (CHC) patients remains unclear.

43 se (ALT) elevation and associated factors in chronic hepatitis C (CHC) patients who achieved undetect

44 istribution and liver disease progression in chronic hepatitis C (CHC) patients with T2D.

45 supplementation on serum fibrotic markers in chronic hepatitis C (CHC) patients.

46 es in metabolic and inflammatory outcomes in chronic hepatitis C (CHC) patients: low-density lipoprot

47 Treatment guidance for chronic hepatitis C (CHC) released by the American Assoc

48 pe of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication f

49 about mortality rates (MRs) in patients with chronic hepatitis C (CHC) with cirrhosis is limited.

50 hort of 4,172 patients, including 3,129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B

51 nic course: n = 17), 12 HIV(+) patients with chronic hepatitis C (CHC), 8 HIV monoinfected individual

52 ith confirmed early PBC, 10 with early stage chronic hepatitis C (CHC), and nine with resolving, self

53 In patients with chronic hepatitis C (CHC), cirrhosis is associated with

54 epatitis C virus (HCV) is a leading cause of chronic hepatitis C (CHC), liver cirrhosis, and hepatoce

55 t hepatitis C virus (HCV) infection leads to chronic hepatitis C (CHC), which often progresses to liv

56 actors influence liver damage progression in chronic hepatitis C (CHC).

57 m treatment decisions in adult patients with chronic hepatitis C (CHC).

58 eated noninvasive tests of liver fibrosis in chronic hepatitis C (CHC).

59 B1 and CB2 gene expression, in patients with chronic hepatitis C (CHC).

60 gical and clinical outcomes in patients with chronic hepatitis C (CHC).

61 play important roles in the pathogenesis of chronic hepatitis C (CHC).

62 We performed a cross-sectional study of chronic hepatitis C (cHCV) patients using tetramer-assoc

63 Despite effective treatment for chronic hepatitis C, deficiencies in diagnosis and acces

64 allenges include increasing awareness of the chronic hepatitis C epidemic, garnering sufficient publi

65 e inhibitors as part of standard therapy for chronic hepatitis C genotype 1 infection, drug-drug inte

66 A total of 3070 treatment-naive, chronic hepatitis C genotype 1-infected patients were tr

67 BV alone in previously untreated adults with chronic hepatitis C genotype 1.

68 ntial Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand.

69 Both HBV and chronic hepatitis C guidelines had greatest increases in

70 terferon (PEG-IFN)-alpha in the treatment of chronic hepatitis C has led to an increase in sustained

71 Therapeutic options for treatment of chronic hepatitis C have improved substantially since th

72 ive models of risk of disease progression in chronic hepatitis C have limited accuracy.

73 Trials of therapies for chronic hepatitis C have used detection of hepatitis C v

74 pproved for response-guided-therapy (RGT) of chronic hepatitis C (HCV) genotype-1-infection in treatm

75 f Ledipasvir/Sofosbuvir for the treatment of chronic hepatitis C (HCV) includes the truncation of the

76 Patients with chronic hepatitis C (HCV) infection have high prevalence

77 Acute and chronic hepatitis C (HCV) infections are prevalent in cu

78 Less is known about its association with chronic hepatitis C (HCV) outcomes.

79 n in retrospective analyses of patients with chronic hepatitis C (HCV).

80 liver damage, especially in individuals with chronic hepatitis C (HCV); however, the impact of nonhea

81 Chronic liver diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liv

82 the management of acute infectious diseases, chronic hepatitis C, human immunodeficiency virus, and a

83 In chronic hepatitis C, IL28B variants associated with poor

84 ong the estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diag

85 Among estimated 150,000 adults living with chronic hepatitis C in Georgia, 52,856 (35.1%) were diag

86 ession analysis, methadone doses (P = .005), chronic hepatitis C-induced cirrhosis (P = .008), and be

87 ors for prolongation of the QTc interval are chronic hepatitis C-induced cirrhosis, higher methadone

88 the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interfe

89 Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older,

90 ould suggest a secondary Mooren ulcer, but a chronic hepatitis C infection was detected.

91 of hepatitis and fibrosis progression during chronic hepatitis C infection, while contrasting results

92 lly effective interferon-free treatments for chronic hepatitis C infection.

93 eks is highly effective for the treatment of chronic hepatitis C infection.

94 ith sickle cell disease are at high risk for chronic hepatitis C infection.

95 diseased livers explanted from patients with chronic hepatitis C infection.

96 nterferon-free regimens for the treatment of chronic hepatitis C infections needs to be evaluated in

97 Chronic hepatitis C is associated with immune infiltrati

98 The treatment of chronic hepatitis C is rapidly evolving from triple ther

99 erexpression of FBP1 in most HCC tumors with chronic hepatitis C is significantly linked with the dec

100 Chronic hepatitis C may follow a mild and stable disease

101 ymorphisms at ITPA and treatment efficacy in chronic hepatitis C mediated by reduced relapse risk.

102 e of chronic hepatitis C by 37% (29-44), and chronic hepatitis C mortality by 14% (3-30) and have pre

103 ame organ (liver) derived from patients with chronic hepatitis C: On the one side, cirrhotic and tumo

104 mbined cohort of non-cirrhotic patients with chronic hepatitis C or alcoholic liver disease (n = 1121

105 An association between male gender and chronic hepatitis C outcome (P value 0.041) was found.

106 The treatment of chronic hepatitis C patients before they developed cirrh

107 The gold standard therapy for chronic hepatitis C patients is pegylated interferon com

108 This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment e

109 Additionally, 3150 (59.1%) chronic hepatitis C patients were immune or vaccinated a

110 Among 5328 chronic hepatitis C patients, 2998 (56.3%) were immune o

111 infected Huh7 cells and in liver tissue from chronic hepatitis C patients.

112 atosteatosis, a common pathology observed in chronic hepatitis C patients.

113 various liver diseases; however, its role in chronic hepatitis C remains unclear.

114 ions' recommendations that all patients with chronic hepatitis C should be treated.

115 n-free, direct-acting antiviral treatment of chronic hepatitis C, subjects who received ribavirin had

116 t has recently been applied to patients with chronic hepatitis C, successfully clearing hepatitis C v

117 rus (HCV) is essential for the management of chronic hepatitis C therapy.

118 evaluate the acute response of patients with chronic hepatitis C to IFN-alpha therapy.

119 notype affects the response of patients with chronic hepatitis C to peginterferon and ribavirin, litt

120 e been reported in liver transplantation and chronic hepatitis C treatment outcomes.

121 Among treatment-naive individuals with chronic hepatitis C viral (HCV) infection and without ci

122 Chronic hepatitis C viral (HCV) infection has been assoc

123 Emerging therapies for chronic hepatitis C viral (HCV) infection involve inhibi

124 ith hepatocellular carcinoma and concomitant chronic hepatitis C viral infection.

125 ced hepatocellular carcinoma and concomitant chronic hepatitis C viral infection.

126 y activity and fibrosis in 551 patients with chronic hepatitis C virus (HCV) and 203 patients with ch

127 Rates of hospitalization due to chronic hepatitis C virus (HCV) are increasing in Canada

128 Many patients with chronic hepatitis C virus (HCV) are on prolonged proton-

129 ring nonalcoholic steatohepatitis (NASH) and chronic hepatitis C virus (HCV) compared to alcohol live

130 efficacy and safety in a phase IIa study in chronic hepatitis C virus (HCV) genotype (GT)-1-infected

131 for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infect

132 proved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infecti

133 proved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infecti

134 hase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and

135 Interferon-free treatment of chronic hepatitis C virus (HCV) genotype 1 infection may

136 telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, in

137 virin in treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.

138 virin (RBV) in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 without cirrh

139 ective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infe

140 lated with pibrentasvir is approved to treat chronic hepatitis C virus (HCV) genotype 1-6 infection i

141 tions are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infec

142 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rat

143 eatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infectio

144 ermine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 i

145 ed regimens in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 4 infection.

146 ear, the landscape of therapy for genotype 1 chronic hepatitis C virus (HCV) has changed dramatically

147 Chronic hepatitis C virus (HCV) has emerged as a threat

148 nomic burden imposed by the complications of chronic hepatitis C virus (HCV) infection - including ci

149 rect-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8-12 wee

150 Treatment of chronic hepatitis C virus (HCV) infection after renal al

151 ng evidence indicates an association between chronic hepatitis C virus (HCV) infection and B-cell lym

152 ns are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis.

153 s is a frequent complication associated with chronic hepatitis C virus (HCV) infection and is a key p

154 previr regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5

155 ole of MAIT cells in livers of patients with chronic hepatitis C virus (HCV) infection and their fate

156 Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of

157 trials have demonstrated that patients with chronic hepatitis C virus (HCV) infection associated HCC

158 Chronic hepatitis C virus (HCV) infection causes a subst

159 Chronic hepatitis C virus (HCV) infection causes decreas

160 Chronic hepatitis C virus (HCV) infection causes inducti

161 ons in the peripheral blood of patients with chronic hepatitis C virus (HCV) infection compared to su

162 An unbiased genome-to-genome analysis in chronic hepatitis C virus (HCV) infection confirms the i

163 Whether chronic hepatitis C virus (HCV) infection decreases humo

164 d neurocognitive impairment in patients with chronic hepatitis C virus (HCV) infection even before li

165 eron-alpha (IFNalpha) has been used to treat chronic hepatitis C virus (HCV) infection for over 20 ye

166 Chronic hepatitis C virus (HCV) infection greatly increa

167 Chronic hepatitis C virus (HCV) infection has become a m

168 Chronic hepatitis C virus (HCV) infection has been impli

169 Although chronic hepatitis C virus (HCV) infection has been treat

170 direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstra

171 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rate

172 Chronic hepatitis C virus (HCV) infection in Asia is cha

173 nd: Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney tran

174 Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney tran

175 interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co

176 Chronic hepatitis C virus (HCV) infection in patients wi

177 to improve access to care and treatment for chronic hepatitis C virus (HCV) infection in resource-li

178 Most persons with chronic hepatitis C virus (HCV) infection in the United

179 Knowledge of the number of persons with chronic hepatitis C virus (HCV) infection in the United

180 herapy can safely prevent the development of chronic hepatitis C virus (HCV) infection in uninfected

181 The existing standard of care for chronic hepatitis C virus (HCV) infection includes the u

182 Chronic hepatitis C virus (HCV) infection is a global he

183 Liver disease as a result of chronic hepatitis C virus (HCV) infection is a global pr

184 Chronic hepatitis C virus (HCV) infection is a leading c

185 BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major bur

186 Chronic hepatitis C virus (HCV) infection is a serious d

187 , interferon-alpha (IFN-alpha) treatment for chronic hepatitis C virus (HCV) infection is an ideal mo

188 Chronic hepatitis C virus (HCV) infection is associated

189 Chronic hepatitis C virus (HCV) infection is associated

190 A key question in care of patients with chronic hepatitis C virus (HCV) infection is beginning t

191 Chronic hepatitis C virus (HCV) infection is characteriz

192 Chronic hepatitis C virus (HCV) infection is characteriz

193 Chronic hepatitis C virus (HCV) infection is characteriz

194 Chronic hepatitis C virus (HCV) infection is characteriz

195 The efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection is determined

196 Treatment for chronic hepatitis C virus (HCV) infection is evolving fr

197 Chronic hepatitis C virus (HCV) infection is frequently

198 Prevalence of chronic hepatitis C virus (HCV) infection is high among

199 and ribavirin (IFN-alpha/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced

200 Chronic hepatitis C virus (HCV) infection is more preval

201 Chronic hepatitis C virus (HCV) infection is one of the

202 Chronic hepatitis C virus (HCV) infection is one of the

203 Chronic hepatitis C virus (HCV) infection is one of the

204 of liver disease in untreated children with chronic hepatitis C virus (HCV) infection is poorly docu

205 The mechanism of how chronic hepatitis C virus (HCV) infection leads to such

206 e status in liver and blood of patients with chronic hepatitis C virus (HCV) infection long after the

207 th human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescri

208 Untreated, chronic hepatitis C virus (HCV) infection may lead to pr

209 Chronic hepatitis C virus (HCV) infection may progress t

210 In Egypt, chronic hepatitis C virus (HCV) infection occurs in arou

211 ere are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients wh

212 The immuno-pathogenic mechanisms of chronic hepatitis C virus (HCV) infection remain to be e

213 Diagnosis of chronic hepatitis C virus (HCV) infection requires both

214 increases treatment efficacy for genotype 1 chronic hepatitis C virus (HCV) infection versus PEG-IFN

215 Chronic hepatitis C virus (HCV) infection with advanced

216 Treatment of chronic hepatitis C virus (HCV) infection with direct-ac

217 ee, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrho

218 For the 8810 patients with chronic hepatitis C virus (HCV) infection, 75% were aged

219 ting antivirals (DAAs) effectively eradicate chronic hepatitis C virus (HCV) infection, although HCV

220 Fibrosis is associated with chronic hepatitis C virus (HCV) infection, although the

221 have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more effi

222 to a high cure rate in treated patients with chronic hepatitis C virus (HCV) infection, but this stil

223 d with clinical and histological features of chronic hepatitis C virus (HCV) infection, including nec

224 nterferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection, increase the

225 For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are cur

226 course of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, we examined t

227 ect-acting antivirals (DAA) for treatment of chronic hepatitis C virus (HCV) infection, we looked at

228 ent standard of care combination therapy for chronic hepatitis C virus (HCV) infection, yet the compo

229 Chronic hepatitis C virus (HCV) infection-associated liv

230 CD4+ T cell failure is a hallmark of chronic hepatitis C virus (HCV) infection.

231 egimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection.

232 and poor physical health among patients with chronic hepatitis C virus (HCV) infection.

233 n associated with liver fibrosis severity in chronic hepatitis C virus (HCV) infection.

234 table ex vivo by conventional methods during chronic hepatitis C virus (HCV) infection.

235 4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) infection.

236 HCC) compared to genotype 2 in patients with chronic hepatitis C virus (HCV) infection.

237 (SVR) is the major end point of therapy for chronic hepatitis C virus (HCV) infection.

238 ation therapy is desirable for patients with chronic hepatitis C virus (HCV) infection.

239 feron-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection.

240 feron alfa remains the central treatment for chronic hepatitis C virus (HCV) infection.

241 uction by CD4(+) T cells in individuals with chronic hepatitis C virus (HCV) infection.

242 sted and overexpress inhibitory molecules in chronic hepatitis C virus (HCV) infection.

243 ve focused on their effects in patients with chronic hepatitis C virus (HCV) infection.

244 Multiple treatments are available for chronic hepatitis C virus (HCV) infection.

245 of liver cirrhosis exists for patients with chronic hepatitis C virus (HCV) infection.

246 or advance in the treatment of patients with chronic hepatitis C virus (HCV) infection.

247 d interferon gamma (IFN-gamma) production in chronic hepatitis C virus (HCV) infection.

248 ents of treatment regimens for patients with chronic hepatitis C virus (HCV) infection.

249 ) play a central role in the pathogenesis of chronic hepatitis C virus (HCV) infection.

250 egimens have been approved for children with chronic hepatitis C virus (HCV) infection.

251 f viral eradication to >90% in patients with chronic hepatitis C virus (HCV) infection.

252 The ability to classify acute versus chronic hepatitis C virus (HCV) infections at the time o

253 All patients with chronic hepatitis C virus (HCV) infections can and shoul

254 nterferon-free regimens for the treatment of chronic hepatitis C virus (HCV) infections require furth

255 The evolution of treatment for patients with chronic hepatitis C virus (HCV) is evolving at a rapid p

256 e direct-acting antivirals (DAA) in treating chronic hepatitis C virus (HCV) is limited by low screen

257 The global burden of disease attributable to chronic hepatitis C virus (HCV) is very large, yet the u

258 1 healthy individuals (NC) (n = 20), group 2 chronic hepatitis C virus (HCV) patients (n = 20), group

259 The optimal retreatment strategy for chronic hepatitis C virus (HCV) patients who fail direct

260 In nontransplant patients with chronic hepatitis C virus (HCV), HCV genotype has been l

261 ntibodies (FPAs) have been well described in chronic hepatitis C virus (HCV), this has not been evalu

262 The mechanisms of chronic hepatitis C virus (HCV)-induced liver fibrosis a

263 the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)-infected patients and th

264 We prospectively evaluated 251 chronic hepatitis C virus (HCV)-infected subjects (31% h

265 hronic liver disease (CLD), and particularly chronic hepatitis C virus (HCV)-related hepatitis.

266 ed risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV).

267 d with human immunodeficiency virus (HIV) or chronic hepatitis C virus (HCV).

268 e who inject drugs in the United States have chronic hepatitis C virus (HCV).

269 predictive of treatment-induced clearance in chronic hepatitis C virus (HCV).

270 virin (RBV) in children and adolescents with chronic hepatitis C virus (HCV).

271 s still regarded as the standard of care for chronic hepatitis C virus (HCV).

272 evir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatm

273 ment for 6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection.

274 afe and highly effective in adolescents with chronic hepatitis C virus genotype 2 or 3 infection.

275 ns with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant reci

276 Chronic hepatitis C virus infection activates an intrahe

277 Sixty six patients with chronic hepatitis C virus infection and eligible for inc

278 Children with chronic hepatitis C virus infection have limited treatme

279 -acting antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortali

280 pulations after DAA therapy in patients with chronic hepatitis C virus infection in the context of th

281 Chronic hepatitis C virus infection is associated with s

282 Chronic hepatitis C virus infection is well-recognized a

283 ffective and well tolerated in patients with chronic hepatitis C virus infection, including those wit

284 nse (SVR) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race

285 direct-acting antiviral drugs used to treat chronic hepatitis C virus infection.

286 ion for therapeutic intervention in treating chronic hepatitis C virus infection.

287 ent has revolutionized care of patients with chronic hepatitis C virus infection.

288 Severe liver disease caused by chronic hepatitis C virus is the major indication for li

289 iling the response to interferon therapy (in chronic Hepatitis C virus patients) and Influenza A viru

290 le degree of liver fibrosis in patients with chronic hepatitis C virus prohibiting cadaveric renal tr

291 acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increa

292 recommendations on the care of patients with chronic hepatitis C virus who have achieved SVR.

293 atocellular carcinoma (HCC) in patients with chronic hepatitis C virus; however, their impact in pati

294 lular carcinoma was overrepresented, whereas chronic hepatitis C was underrepresented, in reported Un

295 ting new direct-acting antivirals (DAAs) for chronic hepatitis C were the major focus of interest at

296 This represents a major difference from chronic hepatitis C, where numerous previous studies hav

297 wo cases of HBV reactivation and one case of chronic hepatitis C, which were successfully treated.

298 s B vaccination among patients in China with chronic hepatitis C who are not in treatment.

299 To address this issue, 126 patients with chronic hepatitis C who completed pegylated IFN plus rib

300 for the treatment of adults with genotype 1 chronic hepatitis C who were prior relapsers.